MENU
+Compare
CRDF
Stock ticker: NASDAQ
AS OF
Aug 28 closing price
Price
$2.08
Change
-$0.09 (-4.15%)
Capitalization
138.37M

CRDF Cardiff Oncology Forecast, Technical & Fundamental Analysis

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need... Show more

CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CRDF with price predictions
Aug 28, 2025

CRDF in +5.15% Uptrend, rising for three consecutive days on August 13, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CRDF advanced for three days, in of 244 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for CRDF just turned positive on August 22, 2025. Looking at past instances where CRDF's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

CRDF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 15, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CRDF as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

CRDF moved below its 50-day moving average on July 29, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CRDF crossed bearishly below the 50-day moving average on August 01, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for CRDF moved below the 200-day moving average on August 15, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CRDF entered a downward trend on August 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.361) is normal, around the industry mean (19.700). P/E Ratio (0.000) is within average values for comparable stocks, (54.040). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.655). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (222.222) is also within normal values, averaging (303.721).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CRDF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CRDF is expected to report earnings to fall 2.95% to -20 cents per share on October 30

Cardiff Oncology CRDF Stock Earnings Reports
Q3'25
Est.
$-0.20
Q2'25
Missed
by $0.02
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.02
The last earnings report on July 29 showed earnings per share of -20 cents, missing the estimate of -18 cents. With 1.11M shares outstanding, the current market capitalization sits at 138.37M.
A.I. Advisor
published General Information

General Information

a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
11055 Flintkote Avenue
Phone
+1 858 952-7570
Employees
32
Web
https://www.cardiffoncology.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BWEL515.001.00
+0.19%
Boswell (J.G.) Co.
NIPMY17.00N/A
N/A
NH Foods Ltd.
SURDF43.24N/A
N/A
Sumitomo Realty & Development Co., Ltd.
VGMIF0.06N/A
N/A
Visible Gold Mines, Inc.
LLKKF0.03N/A
-9.09%
Lake Resources N.L.

CRDF and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with QURE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
-4.15%
QURE - CRDF
42%
Loosely correlated
+3.24%
MRVI - CRDF
42%
Loosely correlated
+2.15%
NAMS - CRDF
42%
Loosely correlated
-2.13%
ORMP - CRDF
39%
Loosely correlated
-0.45%
NRIX - CRDF
37%
Loosely correlated
-1.47%
More